tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Mirum’s deal for Bluejay a positive readthrough to Vir, says Needham
PremiumThe FlyMirum’s deal for Bluejay a positive readthrough to Vir, says Needham
5d ago
Gilead Sciences’ Strong Market Position and Promising Anito-cel Data Support Buy Rating
Premium
Ratings
Gilead Sciences’ Strong Market Position and Promising Anito-cel Data Support Buy Rating
5d ago
Gilead’s Kite presents new analysis on second-line Yescarta therapy
Premium
The Fly
Gilead’s Kite presents new analysis on second-line Yescarta therapy
6d ago
Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital
PremiumThe FlyKelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital
19d ago
Gilead assumed with a Buy at Truist
Premium
The Fly
Gilead assumed with a Buy at Truist
19d ago
Gilead’s Kite Pharma granted orphan designation for multiple myeloma treatment
Premium
The Fly
Gilead’s Kite Pharma granted orphan designation for multiple myeloma treatment
22d ago
Gilead announces delivery of first lenacapavir shipments to Eswatini, Zambia
PremiumThe FlyGilead announces delivery of first lenacapavir shipments to Eswatini, Zambia
25d ago
Gilead Sciences: Promising Future in HIV Treatment and Oncology Drives Buy Rating
Premium
Ratings
Gilead Sciences: Promising Future in HIV Treatment and Oncology Drives Buy Rating
29d ago
Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects
Premium
Ratings
Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects
30d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100